Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has provided an announcement.
Venus Medtech has announced a major transaction involving the disposal of property related to its Qiming Healthcare Life Science Industrial Park project, selling it for RMB374,563,969. This move aligns with the company’s strategic shift to concentrate on its core heart valve business, following a previously recognized impairment loss of RMB126.0 million related to the project.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company based in China, primarily engaged in the medical technology industry with a focus on the development and production of heart valve products.
Average Trading Volume: 3,725,084
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.03B
Learn more about 2500 stock on TipRanks’ Stock Analysis page.